They Call It a Lottery Ticket. The Data Says Otherwise | D.A. Wallach on The Hidden Alpha of Biotech

Biotech is one of the few areas in investing where specialized knowledge may still generate persistent alpha. In this episode of Excess Returns, D.A. Wallach, venture capitalist and co-founder of Time BioVentures, joins us to explain how biotech investing works, why development-stage drug companies behave like portfolios of options, and why specialist investors play such a large role in this market. We also explore the cycles that have driven biotech performance, the impact of interest rates and capital flows, and how AI and global competition may reshape the industry in the years ahead.D.A. Wallach – Twitterhttps://x.com/DAWallachTopics covered include• Why biotech may be one of the last areas where specialist investors can generate persistent alpha• The “bag of options” framework for valuing development-stage biotech companies• How probabilities of drug success and clinical base rates drive biotech valuations• Why rising interest rates hit biotech stocks harder than many other sectors• How capital flows and investor narratives create boom-and-bust cycles in biotech• What happened to biotech during the pandemic surge and the post-COVID downturn• Why AI and tech narratives compete with biotech for investor attention• The role of specialist biotech hedge funds in the public markets• How large pharmaceutical companies drive returns through biotech acquisitions• Differences between biotech venture capital and traditional tech venture investing• How venture investors evaluate drug development programs and scientific evidence• Portfolio construction and diversification when investing in highly uncertain biotech companies• The emerging role of China in clinical trials and global drug development• Whether AI can improve drug discovery, clinical trials, and pharmaceutical R&D productivity• Why investors should avoid rigid value vs growth ideologies and stay adaptableTimestamps00:00 Why biotech investing requires specialized knowledge01:40 Is biotech one of the last places for persistent active alpha?02:45 The “bag of options” model for valuing biotech companies05:00 Drug development phases and probabilities of success07:00 Using base rates to estimate clinical trial success09:20 Estimating total addressable markets for new drugs11:10 Why rising interest rates hurt biotech valuations13:00 Capital flows and why biotech underperformed in recent years15:30 The biotech boom and bust around the COVID pandemic18:00 How AI and tech compete with biotech for investor capital22:20 The role of specialist biotech hedge funds24:00 How pharmaceutical acquisitions drive biotech returns25:20 How biotech venture capital differs from tech VC30:50 Why biotech investors must evaluate complex scientific data34:20 Where AI may improve drug discovery and R&D productivity42:00 Portfolio construction and diversification in biotech venture investing44:30 Volatility, valuation marks, and private market pricing48:00 Managing risk across different drug technologies and disease areas49:30 Why China is becoming important for clinical trials53:00 Why biotech investing must be viewed as a global industry54:30 The importance of flexibility between value and growth investing58:50 Will investing become more systematic and quantitative over time